nodes	percent_of_prediction	percent_of_DWPC	metapath
Niflumic Acid—PTGS2—bile duct cancer	0.975	1	CbGaD
Niflumic Acid—Floctafenine—PTGS2—bile duct cancer	0.00398	0.719	CrCbGaD
Niflumic Acid—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—KRT19—bile duct cancer	0.00189	0.0975	CbGpPWpGaD
Niflumic Acid—Mefenamic acid—PTGS2—bile duct cancer	0.00155	0.281	CrCbGaD
Niflumic Acid—SLC16A1—Pyruvate metabolism and Citric Acid (TCA) cycle—IDH2—bile duct cancer	0.00121	0.0626	CbGpPWpGaD
Niflumic Acid—PTGS2—Signaling mediated by p38-alpha and p38-beta—KRT19—bile duct cancer	0.00101	0.0523	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism of lipids and lipoproteins—FAR2—bile duct cancer	0.000557	0.0288	CbGpPWpGaD
Niflumic Acid—SLC16A1—The citric acid (TCA) cycle and respiratory electron transport—IDH2—bile duct cancer	0.00047	0.0243	CbGpPWpGaD
Niflumic Acid—CLCNKA—Transmembrane transport of small molecules—SLC5A5—bile duct cancer	0.00043	0.0222	CbGpPWpGaD
Niflumic Acid—SLC16A7—SLC-mediated transmembrane transport—SLC5A5—bile duct cancer	0.000396	0.0205	CbGpPWpGaD
Niflumic Acid—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—bile duct cancer	0.000384	0.0198	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—NOS2—bile duct cancer	0.000371	0.0192	CbGpPWpGaD
Niflumic Acid—CLCNKA—Transmembrane transport of small molecules—GNAS—bile duct cancer	0.000334	0.0173	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Prostaglandin Synthesis and Regulation—PTGS2—bile duct cancer	0.000309	0.0159	CbGpPWpGaD
Niflumic Acid—PTGS1—Overview of nanoparticle effects—PTGS2—bile duct cancer	0.0003	0.0155	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—PTGS2—bile duct cancer	0.000273	0.0141	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Platelet homeostasis—GNAS—bile duct cancer	0.000268	0.0138	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism of lipids and lipoproteins—FAR2—bile duct cancer	0.000254	0.0131	CbGpPWpGaD
Niflumic Acid—PTGS1—Eicosanoid Synthesis—PTGS2—bile duct cancer	0.000249	0.0129	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—FAR2—bile duct cancer	0.000248	0.0128	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism of lipids and lipoproteins—IDH1—bile duct cancer	0.000234	0.0121	CbGpPWpGaD
Niflumic Acid—PLA2G4A—AGE/RAGE pathway—NOS2—bile duct cancer	0.000223	0.0115	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Fc-epsilon receptor I signaling in mast cells—HRAS—bile duct cancer	0.000219	0.0113	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism of lipids and lipoproteins—FAR2—bile duct cancer	0.00021	0.0109	CbGpPWpGaD
Niflumic Acid—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—bile duct cancer	0.000208	0.0108	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Arachidonic acid metabolism—PTGS2—bile duct cancer	0.000205	0.0106	CbGpPWpGaD
Niflumic Acid—SLC16A7—Transmembrane transport of small molecules—SLC5A5—bile duct cancer	0.000201	0.0104	CbGpPWpGaD
Niflumic Acid—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—bile duct cancer	0.000199	0.0103	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Platelet homeostasis—NOS2—bile duct cancer	0.000195	0.0101	CbGpPWpGaD
Niflumic Acid—PLA2G4A—AGE/RAGE pathway—MMP2—bile duct cancer	0.000192	0.0099	CbGpPWpGaD
Niflumic Acid—UGT1A9—NRF2 pathway—SLC5A5—bile duct cancer	0.000173	0.00893	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism of lipids and lipoproteins—FAR2—bile duct cancer	0.000171	0.00885	CbGpPWpGaD
Niflumic Acid—SLC16A1—SLC-mediated transmembrane transport—SLC5A5—bile duct cancer	0.000169	0.00873	CbGpPWpGaD
Niflumic Acid—PTGS1—Overview of nanoparticle effects—IL6—bile duct cancer	0.000164	0.00846	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—bile duct cancer	0.000162	0.00839	CbGpPWpGaD
Niflumic Acid—PLA2G4A—p38 MAPK Signaling Pathway—HRAS—bile duct cancer	0.000159	0.00821	CbGpPWpGaD
Niflumic Acid—SLC16A7—Transmembrane transport of small molecules—GNAS—bile duct cancer	0.000156	0.00808	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—FAR2—bile duct cancer	0.000145	0.0075	CbGpPWpGaD
Niflumic Acid—PLA2G4A—AGE/RAGE pathway—MMP9—bile duct cancer	0.000144	0.00744	CbGpPWpGaD
Niflumic Acid—PLA2G4A—PDGF Pathway—HRAS—bile duct cancer	0.000142	0.00736	CbGpPWpGaD
Niflumic Acid—UGT1A9—NRF2 pathway—TGFBR2—bile duct cancer	0.000139	0.00719	CbGpPWpGaD
Niflumic Acid—PTGS1—Arachidonic acid metabolism—PTGS2—bile duct cancer	0.000139	0.00716	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism of lipids and lipoproteins—FAR2—bile duct cancer	0.000136	0.00702	CbGpPWpGaD
Niflumic Acid—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TGFB1—bile duct cancer	0.000131	0.00679	CbGpPWpGaD
Niflumic Acid—PTGS2—Overview of nanoparticle effects—IL6—bile duct cancer	0.00013	0.00671	CbGpPWpGaD
Niflumic Acid—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—bile duct cancer	0.000129	0.00665	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—SMAD4—bile duct cancer	0.000128	0.00663	CbGpPWpGaD
Niflumic Acid—UGT1A9—NRF2 pathway—HGF—bile duct cancer	0.000128	0.00661	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—IDH2—bile duct cancer	0.000121	0.00626	CbGpPWpGaD
Niflumic Acid—SLC16A1—Cell surface interactions at the vascular wall—NRAS—bile duct cancer	0.000119	0.00614	CbGpPWpGaD
Niflumic Acid—PLA2G4A—AGE/RAGE pathway—EGFR—bile duct cancer	0.000116	0.00602	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—FAR2—bile duct cancer	0.000113	0.00583	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Platelet activation, signaling and aggregation—HGF—bile duct cancer	0.000111	0.00572	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism of lipids and lipoproteins—IDH1—bile duct cancer	0.000106	0.0055	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—IDH1—bile duct cancer	0.000104	0.00538	CbGpPWpGaD
Niflumic Acid—SLC16A1—Cell surface interactions at the vascular wall—KRAS—bile duct cancer	0.000102	0.00528	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—HRAS—bile duct cancer	9.96e-05	0.00514	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Endothelins—HRAS—bile duct cancer	9.7e-05	0.00501	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—FAR2—bile duct cancer	9.35e-05	0.00483	CbGpPWpGaD
Niflumic Acid—PTGS2—Aryl Hydrocarbon Receptor—NRAS—bile duct cancer	9.15e-05	0.00473	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism of lipids and lipoproteins—IDH1—bile duct cancer	8.82e-05	0.00456	CbGpPWpGaD
Niflumic Acid—PTGS1—Selenium Micronutrient Network—PTGS2—bile duct cancer	8.81e-05	0.00455	CbGpPWpGaD
Niflumic Acid—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—bile duct cancer	8.71e-05	0.0045	CbGpPWpGaD
Niflumic Acid—SLC16A1—Cell surface interactions at the vascular wall—HRAS—bile duct cancer	8.69e-05	0.00449	CbGpPWpGaD
Niflumic Acid—SLC16A1—Transmembrane transport of small molecules—SLC5A5—bile duct cancer	8.59e-05	0.00444	CbGpPWpGaD
Niflumic Acid—PTGS2—Aryl Hydrocarbon Receptor—EGFR—bile duct cancer	8.33e-05	0.00431	CbGpPWpGaD
Niflumic Acid—PTGS2—Aryl Hydrocarbon Receptor—KRAS—bile duct cancer	7.87e-05	0.00407	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—GNAS—bile duct cancer	7.71e-05	0.00398	CbGpPWpGaD
Niflumic Acid—PLA2G4A—PDGFR-beta signaling pathway—NRAS—bile duct cancer	7.67e-05	0.00396	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—FAR2—bile duct cancer	7.63e-05	0.00394	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—NOS2—bile duct cancer	7.52e-05	0.00389	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—HGF—bile duct cancer	7.34e-05	0.00379	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism of lipids and lipoproteins—IDH1—bile duct cancer	7.19e-05	0.00372	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—ERBB2—bile duct cancer	7.18e-05	0.00371	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—IDH2—bile duct cancer	7.09e-05	0.00366	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—bile duct cancer	7.02e-05	0.00363	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—SMAD4—bile duct cancer	6.88e-05	0.00355	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—SLC5A5—bile duct cancer	6.87e-05	0.00355	CbGpPWpGaD
Niflumic Acid—PTGS2—Aryl Hydrocarbon Receptor—HRAS—bile duct cancer	6.69e-05	0.00346	CbGpPWpGaD
Niflumic Acid—SLC16A1—Transmembrane transport of small molecules—GNAS—bile duct cancer	6.67e-05	0.00345	CbGpPWpGaD
Niflumic Acid—PLA2G4A—PDGFR-beta signaling pathway—KRAS—bile duct cancer	6.6e-05	0.00341	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	6.44e-05	0.00333	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—IDH1—bile duct cancer	6.1e-05	0.00315	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—FAR2—bile duct cancer	6.05e-05	0.00313	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—GNAS—bile duct cancer	5.99e-05	0.0031	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—HGF—bile duct cancer	5.71e-05	0.00295	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism of lipids and lipoproteins—IDH1—bile duct cancer	5.71e-05	0.00295	CbGpPWpGaD
Niflumic Acid—PTGS2—C-MYB transcription factor network—NRAS—bile duct cancer	5.65e-05	0.00292	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—NOS2—bile duct cancer	5.63e-05	0.00291	CbGpPWpGaD
Niflumic Acid—PLA2G4A—PDGFR-beta signaling pathway—HRAS—bile duct cancer	5.61e-05	0.0029	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—IDH2—bile duct cancer	5.51e-05	0.00285	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—GNAS—bile duct cancer	5.34e-05	0.00276	CbGpPWpGaD
Niflumic Acid—UGT1A9—NRF2 pathway—TGFB1—bile duct cancer	5.21e-05	0.00269	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—TGFB1—bile duct cancer	5.07e-05	0.00262	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—bile duct cancer	4.98e-05	0.00257	CbGpPWpGaD
Niflumic Acid—PTGS2—C-MYB transcription factor network—KRAS—bile duct cancer	4.86e-05	0.00251	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—MMP9—bile duct cancer	4.85e-05	0.00251	CbGpPWpGaD
Niflumic Acid—PTGS1—Selenium Micronutrient Network—IL6—bile duct cancer	4.8e-05	0.00248	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—IDH1—bile duct cancer	4.74e-05	0.00245	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—KRAS—bile duct cancer	4.7e-05	0.00243	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—RNF43—bile duct cancer	4.61e-05	0.00238	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—IDH2—bile duct cancer	4.57e-05	0.00236	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Platelet activation, signaling and aggregation—TGFB1—bile duct cancer	4.52e-05	0.00233	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—NOS2—bile duct cancer	4.38e-05	0.00226	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—bile duct cancer	4.18e-05	0.00216	CbGpPWpGaD
Niflumic Acid—PTGS2—C-MYB transcription factor network—HRAS—bile duct cancer	4.13e-05	0.00214	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—SLC5A5—bile duct cancer	4.02e-05	0.00208	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—TGFB1—bile duct cancer	4e-05	0.00207	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—IDH1—bile duct cancer	3.93e-05	0.00203	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—EGFR—bile duct cancer	3.92e-05	0.00203	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—bile duct cancer	3.85e-05	0.00199	CbGpPWpGaD
Niflumic Acid—PTGS2—Selenium Micronutrient Network—IL6—bile duct cancer	3.81e-05	0.00197	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—IDH2—bile duct cancer	3.72e-05	0.00192	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—RNF43—bile duct cancer	3.53e-05	0.00182	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—GNAS—bile duct cancer	3.44e-05	0.00178	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—TP53—bile duct cancer	3.29e-05	0.0017	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—NRAS—bile duct cancer	3.22e-05	0.00166	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—IDH1—bile duct cancer	3.2e-05	0.00165	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—SLC5A5—bile duct cancer	3.13e-05	0.00162	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—GNAS—bile duct cancer	3.13e-05	0.00162	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—IDH1—bile duct cancer	3.04e-05	0.00157	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—IL6—bile duct cancer	3.01e-05	0.00156	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—TGFB1—bile duct cancer	2.99e-05	0.00155	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—IDH2—bile duct cancer	2.96e-05	0.00153	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	2.93e-05	0.00151	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—PTGS2—bile duct cancer	2.87e-05	0.00148	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—KRAS—bile duct cancer	2.77e-05	0.00143	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—bile duct cancer	2.72e-05	0.00141	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—bile duct cancer	2.67e-05	0.00138	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—SLC5A5—bile duct cancer	2.59e-05	0.00134	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—IDH1—bile duct cancer	2.54e-05	0.00131	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—bile duct cancer	2.52e-05	0.0013	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—NRAS—bile duct cancer	2.5e-05	0.00129	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—TP53—bile duct cancer	2.46e-05	0.00127	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—GNAS—bile duct cancer	2.43e-05	0.00126	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	2.43e-05	0.00125	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—HRAS—bile duct cancer	2.36e-05	0.00122	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—TGFB1—bile duct cancer	2.33e-05	0.0012	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—bile duct cancer	2.24e-05	0.00116	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—KRAS—bile duct cancer	2.16e-05	0.00111	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—SLC5A5—bile duct cancer	2.11e-05	0.00109	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—TGFBR2—bile duct cancer	2.11e-05	0.00109	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—GNAS—bile duct cancer	2.03e-05	0.00105	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—GNAS—bile duct cancer	2.01e-05	0.00104	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—SMAD4—bile duct cancer	1.99e-05	0.00103	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	1.98e-05	0.00102	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—TP53—bile duct cancer	1.92e-05	0.00099	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—HRAS—bile duct cancer	1.83e-05	0.000947	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—PTGS2—bile duct cancer	1.68e-05	0.000867	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—SLC5A5—bile duct cancer	1.68e-05	0.000867	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—GNAS—bile duct cancer	1.64e-05	0.000848	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—TGFBR2—bile duct cancer	1.61e-05	0.000834	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—SMAD4—bile duct cancer	1.53e-05	0.000789	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—NRAS—bile duct cancer	1.44e-05	0.000743	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—EGFR—bile duct cancer	1.31e-05	0.000677	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—PTGS2—bile duct cancer	1.31e-05	0.000675	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—GNAS—bile duct cancer	1.3e-05	0.000673	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—KRAS—bile duct cancer	1.24e-05	0.000639	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—NOS2—bile duct cancer	1.14e-05	0.000587	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—ERBB2—bile duct cancer	1.12e-05	0.000577	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—PTGS2—bile duct cancer	1.08e-05	0.000559	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—HRAS—bile duct cancer	1.05e-05	0.000543	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—IL6—bile duct cancer	1.01e-05	0.00052	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—MMP9—bile duct cancer	9.57e-06	0.000495	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—PTGS2—bile duct cancer	8.82e-06	0.000456	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—ERBB2—bile duct cancer	8.55e-06	0.000442	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—NRAS—bile duct cancer	8.49e-06	0.000439	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—TGFB1—bile duct cancer	7.89e-06	0.000408	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—EGFR—bile duct cancer	7.74e-06	0.0004	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—KRAS—bile duct cancer	7.31e-06	0.000378	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—NRAS—bile duct cancer	6.5e-06	0.000336	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—TP53—bile duct cancer	6.5e-06	0.000336	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—HRAS—bile duct cancer	6.21e-06	0.000321	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—TGFB1—bile duct cancer	6.04e-06	0.000312	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—IL6—bile duct cancer	5.95e-06	0.000307	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—EGFR—bile duct cancer	5.92e-06	0.000306	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—KRAS—bile duct cancer	5.6e-06	0.000289	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—HRAS—bile duct cancer	4.76e-06	0.000246	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—IL6—bile duct cancer	4.55e-06	0.000235	CbGpPWpGaD
